These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 2654134)
1. Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells. Walewski J; Paietta E; Dutcher J; Wiernik PH J Cancer Res Clin Oncol; 1989; 115(2):170-4. PubMed ID: 2654134 [TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique. Favrot MC; Coze C; Combaret V; Gaspard M; Colin C; Franks C; Negrier S; Philip I; Philip T Mol Biother; 1990 Mar; 2(1):32-7. PubMed ID: 2185792 [TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630 [TBL] [Abstract][Full Text] [Related]
4. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379 [TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429 [TBL] [Abstract][Full Text] [Related]
6. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Shuman WP; Levitt D; Fefer A Cancer Res; 1989 Jan; 49(1):235-40. PubMed ID: 2783243 [TBL] [Abstract][Full Text] [Related]
7. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835 [TBL] [Abstract][Full Text] [Related]
8. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes. Flexman JP; Manning LS; Robinson BW Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789 [TBL] [Abstract][Full Text] [Related]
9. A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients. Cascinelli N; Belli F; Marchini S; Marolda R; Prada A; Sciorelli G; Villani F; Gambacorti-Passerini C; Galazka A; Parmiani G Tumori; 1989 Jun; 75(3):233-44. PubMed ID: 2788945 [TBL] [Abstract][Full Text] [Related]
10. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy. Klasa RJ; Silver HK; Kong S Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154 [TBL] [Abstract][Full Text] [Related]
11. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2. Topalian SL; Rosenberg SA Acta Haematol; 1987; 78 Suppl 1():75-6. PubMed ID: 3124451 [TBL] [Abstract][Full Text] [Related]
12. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862 [TBL] [Abstract][Full Text] [Related]
13. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432 [TBL] [Abstract][Full Text] [Related]